within Pharmacolibrary.Drugs.ATC.V;

model V03AB09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.5333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AB09</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dimercaprol (British anti-Lewisite, BAL) is a chelating agent developed during World War II as an antidote to arsenic-based chemical warfare agents. It is primarily used for the treatment of acute poisoning by heavy metals like arsenic, mercury, gold, and, in combination with other agents, lead. Dimercaprol is not widely used today due to the availability of better-tolerated oral chelators, but can be used in emergencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, following typical intramuscular dosing.</p><h4>References</h4><ol><li><p>Mückter, H, et al., &amp; Fichtl, B (1997). Are we ready to replace dimercaprol (BAL) as an arsenic antidote?. <i>Human &amp; experimental toxicology</i> 16(8) 460–465. DOI:<a href=\"https://doi.org/10.1177/096032719701600807\">10.1177/096032719701600807</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9292286/\">https://pubmed.ncbi.nlm.nih.gov/9292286</a></p></li><li><p>Vale, JA, &amp; Meredith, TJ (1986). Antidotal therapy: pharmacokinetic aspects. <i>Developments in toxicology and environmental science</i> 12 329–338. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3549234/\">https://pubmed.ncbi.nlm.nih.gov/3549234</a></p></li><li><p>Volf, V, et al., &amp; Singh, PK (1995). Combined chelation treatment for polonium after simulated wound contamination in rat. <i>International journal of radiation biology</i> 68(4) 395–404. DOI:<a href=\"https://doi.org/10.1080/09553009514551341\">10.1080/09553009514551341</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7594964/\">https://pubmed.ncbi.nlm.nih.gov/7594964</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AB09;
